Reversible arrhythmias observed in patients treated with recombinant alpha 2 interferon.
We have treated 25 patients, 7 with breast cancer and 18 with non-Hodgkin's lymphoma, with recombinant alpha 2 interferon. In 5 patients we observed cardiac arrhythmias that were unexpected and required treatment. No deaths have occurred that we can attribute to interferon, though 1 patient had to be resuscitated. Age, prior cardiac disease, prior treatment with doxorubicin, and interferon dose appear to be predisposing factors for this toxicity.
D000368:Aged; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D001943:Breast Neoplasms / Q000628:therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects* / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D007370:Interferon Type I; D011994:Recombinant Proteins